Status:
COMPLETED
Trial of Combined Aerobic and Resistance Exercise in Breast Cancer Survivors
Lead Sponsor:
AHS Cancer Control Alberta
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
Endurance exercise such as walking has been shown to help breast cancer survivors maintain their energy and quality of life while they are receiving chemotherapy, but there have not been any studies o...
Detailed Description
BACKGROUND: Aerobic exercise has been shown to improve physical fitness and quality of life (QoL) in breast cancer survivors receiving chemotherapy but no study to date has examined the addition of re...
Eligibility Criteria
Inclusion
- Are diagnosed with stage I-IIIA breast cancer, histologically confirmed
- Are scheduled to receive adjuvant chemotherapy (receiving neoadjuvant chemotherapy for locally advanced cancer is an exclusion criteria)
- Have not received previous chemotherapy (previous cancer is NOT an exclusion criteria)
- Have not received transabdominal rectus abdominis muscle (TRAM) reconstructive surgery
- Are 18 years or older
- Received approval from their treating oncologist
- No uncontrolled hypertension, cardiac illness or psychiatric condition or any other medical condition that would be a contraindication to exercise
- Able to understand and provide written informed consent in English or French (Ottawa)
- Complete maximal aerobic and strength tests. No contraindication to exercise as determined by fitness tests
- Are not pregnant
- Willing to accept randomization and complete their assigned exercise program
- If participant is currently exercising (e.g., swimming at the Y 3 times per week) must be willing to give this up in place of their randomly assigned program
- Willing to travel to fitness center 3 times/week to complete exercise program
- Willing to complete all assessments (except blood) at all timepoints including 6, 12, and 24 month follow-ups
- Must not have a planned/known absence of greater than 2 weeks during the intended intervention period and must be able/willing to perform exercise sessions on their own during any planned absences of less than 2 weeks
Exclusion
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2014
Estimated Enrollment :
301 Patients enrolled
Trial Details
Trial ID
NCT00249015
Start Date
January 1 2008
End Date
March 1 2014
Last Update
July 18 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2